Cargando…
Lysosomes as a Target of Anticancer Therapy
Lysosomes are organelles containing acidic hydrolases that are responsible for lysosomal degradation and the maintenance of cellular homeostasis. They play an important role in autophagy, as well as in various cell death pathways, such as lysosomal and apoptotic death. Various agents, including drug...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916765/ https://www.ncbi.nlm.nih.gov/pubmed/36768500 http://dx.doi.org/10.3390/ijms24032176 |
_version_ | 1784886205462085632 |
---|---|
author | Trybus, Wojciech Trybus, Ewa Król, Teodora |
author_facet | Trybus, Wojciech Trybus, Ewa Król, Teodora |
author_sort | Trybus, Wojciech |
collection | PubMed |
description | Lysosomes are organelles containing acidic hydrolases that are responsible for lysosomal degradation and the maintenance of cellular homeostasis. They play an important role in autophagy, as well as in various cell death pathways, such as lysosomal and apoptotic death. Various agents, including drugs, can induce lysosomal membrane permeability, resulting in the translocation of acidic hydrolases into the cytoplasm, which promotes lysosomal-mediated death. This type of death may be of great importance in anti-cancer therapy, as both cancer cells with disturbed pathways leading to apoptosis and drug-resistant cells can undergo it. Important compounds that damage the lysosomal membrane include lysosomotropic compounds, antihistamines, immunosuppressants, DNA-damaging drugs, chemotherapeutics, photosensitizers and various plant compounds. An interesting approach in the treatment of cancer and the search for ways to overcome the chemoresistance of cancer cells may also be combining lysosomotropic compounds with targeted modulators of autophagy to induce cell death. These compounds may be an alternative in oncological treatment, and lysosomes may become a promising therapeutic target for many diseases, including cancer. Understanding the functional relationships between autophagy and apoptosis and the possibilities of their regulation, both in relation to normal and cancer cells, can be used to develop new and more effective anticancer therapies. |
format | Online Article Text |
id | pubmed-9916765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99167652023-02-11 Lysosomes as a Target of Anticancer Therapy Trybus, Wojciech Trybus, Ewa Król, Teodora Int J Mol Sci Review Lysosomes are organelles containing acidic hydrolases that are responsible for lysosomal degradation and the maintenance of cellular homeostasis. They play an important role in autophagy, as well as in various cell death pathways, such as lysosomal and apoptotic death. Various agents, including drugs, can induce lysosomal membrane permeability, resulting in the translocation of acidic hydrolases into the cytoplasm, which promotes lysosomal-mediated death. This type of death may be of great importance in anti-cancer therapy, as both cancer cells with disturbed pathways leading to apoptosis and drug-resistant cells can undergo it. Important compounds that damage the lysosomal membrane include lysosomotropic compounds, antihistamines, immunosuppressants, DNA-damaging drugs, chemotherapeutics, photosensitizers and various plant compounds. An interesting approach in the treatment of cancer and the search for ways to overcome the chemoresistance of cancer cells may also be combining lysosomotropic compounds with targeted modulators of autophagy to induce cell death. These compounds may be an alternative in oncological treatment, and lysosomes may become a promising therapeutic target for many diseases, including cancer. Understanding the functional relationships between autophagy and apoptosis and the possibilities of their regulation, both in relation to normal and cancer cells, can be used to develop new and more effective anticancer therapies. MDPI 2023-01-22 /pmc/articles/PMC9916765/ /pubmed/36768500 http://dx.doi.org/10.3390/ijms24032176 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Trybus, Wojciech Trybus, Ewa Król, Teodora Lysosomes as a Target of Anticancer Therapy |
title | Lysosomes as a Target of Anticancer Therapy |
title_full | Lysosomes as a Target of Anticancer Therapy |
title_fullStr | Lysosomes as a Target of Anticancer Therapy |
title_full_unstemmed | Lysosomes as a Target of Anticancer Therapy |
title_short | Lysosomes as a Target of Anticancer Therapy |
title_sort | lysosomes as a target of anticancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916765/ https://www.ncbi.nlm.nih.gov/pubmed/36768500 http://dx.doi.org/10.3390/ijms24032176 |
work_keys_str_mv | AT trybuswojciech lysosomesasatargetofanticancertherapy AT trybusewa lysosomesasatargetofanticancertherapy AT krolteodora lysosomesasatargetofanticancertherapy |